Potent inhibition of SARS-CoV-2 proteases PL and 3CL by selected gold(III)-dithiocarbamato complexes showing strong and selective antiviral activity against HCoV-OC43.

Potent inhibition of SARS-CoV-2 proteases PL and 3CL by selected gold(III)-dithiocarbamato complexes showing strong and selective antiviral activity against HCoV-OC43.

Publication date: Dec 01, 2025

Selected gold(III)-dithiocarbamato complexes were identified as potent inhibitors of two critical enzymes involved in the SARS-CoV-2 replication cycle, the papain-line protease (PL) and the 3-chymotrypsin-like protease (3CL), showing exceptional inhibition of PL with IC values in the range of 0. 1-0. 2 μM and rather moderate activity against 3CL (IC values 8-9 μM). Crucially, the inhibitory activity could be attributed to the presence of the gold(III) centre, as the gold-free dithiocarbamato ligand showed no significant activity against either proteases. The toxicity toward host cells, cellular uptake, and antiviral activity against the HCoV-OC43 coronavirus of the complexes were generally in good correlation to one another. Complexes Au-1 and Au-2 stood out as a highly active antiviral agents with a selectivity index above 90.

Concepts Keywords
Antiviral 3C-like proteinase, SARS-CoV-2
Biochem 3CL(pro)
Coronavirus Antiviral
Oc43 Antiviral Agents
Potent Antiviral Agents
Coordination Complexes
Coordination Complexes
Coronavirus
Coronavirus 3C Proteases
Coronavirus 3C Proteases
Coronavirus OC43, Human
Coronavirus Papain-Like Proteases
Coronavirus Papain-Like Proteases
COVID-19 Drug Treatment
Gold
Gold
Gold(III) dithiocarbamates
Humans
Organogold Compounds
Organogold Compounds
papain-like protease, SARS-CoV-2
PL(pro)
Protease Inhibitors
Protease Inhibitors
SARS-CoV-2
Thiocarbamates
Thiocarbamates
Vero Cells

Semantics

Type Source Name
disease MESH COVID-19
disease IDO host
drug DRUGBANK Papain
disease IDO replication
drug DRUGBANK Gold

Original Article

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *